There were 1,611 press releases posted in the last 24 hours and 442,743 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image